The cheapest legitimate way to buy semaglutide in August 2026 is the oral version: NovoCare Pharmacy sells the Wegovy pill for $149 a month at the 1.5 mg starter dose and $299 at the full 25 mg dose, no insurance required. For the injection, the manufacturer's own cash price is $349 a month, a 12-month telehealth subscription brings that to $249, and commercial insurance that genuinely covers Wegovy puts most people at $0 to $25. The route to avoid is retail cash with no program attached, which runs about $1,349 a month at list price.
Semaglutide is prescription-only in every legitimate channel in the United States. That single fact sorts everything below: each lane starts with a prescriber, and what separates them is price, contract length, and how much paperwork sits between you and the box. This page routes you to the right lane. If you already know which one you want, the detailed pages are linked from each section.
The honest caveat: compounded semaglutide is the same active molecule as the branded drug but is not FDA-approved. If your insurance covers a branded GLP-1, that route is cheaper and we earn nothing from it.
See if you qualify →Partner link: we may earn a commission at no extra cost to you. Prices checked 24 August 2026.
Every semaglutide route in one table
| Route | Cost per month (Aug 2026) | Rx required | Best for | The catch |
|---|---|---|---|---|
| Retail pharmacy, plan covers it | $0–$25 with savings card | Yes | Anyone with commercial coverage for obesity drugs | Prior authorisation and BMI documentation are near-universal |
| Medicare GLP-1 Bridge | $50 | Yes | Medicare beneficiaries meeting BMI and comorbidity criteria | Runs through 31 Dec 2027; prior auth attestation required |
| Wegovy pill / Ozempic pill (cash) | $149 starter, $199 mid, $299 top dose | Yes | Cash payers who do not want injections | Daily tablet, strict fasted-dosing rules |
| NovoCare Pharmacy, Wegovy pen (cash) | $349 ($199 for first 2 fills) | Yes | Cash payers who want the branded injection | Self-pay only, cannot be combined with insurance |
| Telehealth subscription (Ro, LifeMD, WW) | $329 / $299 / $249 for 3, 6 or 12 months | Yes | Cash payers willing to prepay a term | Same brand drug; you are locked into the term |
| Retail cash, no program | ~$1,349 list | Yes | Nobody, if any option above is open to you | Roughly 4x the manufacturer's own cash price |
| Personalised 503A compounding | Not publicly listed; varies by pharmacy | Yes | Documented clinical need brand cannot meet | Narrow, contested, and under active FDA pressure |
| Research-peptide vendors | Below every regulated channel | No | Not a route this site recommends | Sold as not for human use; unapproved, unverified |
Prices are from NovoCare Pharmacy, TrumpRx and Novo Nordisk announcements, checked August 2026. A "month" means one box of four pens or one bottle of 30 tablets.
Insurance is still the cheapest lane, if your plan is one of the ones that says yes
If your commercial plan covers semaglutide for weight management, nothing else competes. The Novo Nordisk savings card takes eligible commercially insured patients down to as little as $25 a month, with maximum savings of $100 a month off your copay.
The obstacle is coverage itself, not the copay. In 2025, 19% of firms with 200 or more workers and 43% of firms with 5,000 or more covered GLP-1s for weight loss in their largest plan, per the KFF and Peterson Center employer survey. Nearly all of those plans require prior authorisation with BMI and comorbidity documentation.
Two things worth knowing before you call your plan. Federal and state programme enrollees, including Medicare, Medicaid, VA and TRICARE, cannot use the savings card. And card savings do not count toward your deductible or out-of-pocket maximum. Our GLP-1 coupons and savings guide walks through the eligibility fine print.
Medicare now has a lane, and it is $50
Medicare began covering GLP-1s for obesity on 1 July 2026 through the GLP-1 Bridge, a temporary programme now extended through 31 December 2027. Eligible beneficiaries pay $50 a month. Manufacturers agreed to supply at a net price of $245 a month under the BALANCE framework that sits behind it.
You need to meet BMI and comorbidity criteria, and your prescriber has to submit a prior authorisation attesting to medical necessity. The broader BALANCE model in Part D was delayed indefinitely for lack of plan participation, so the Bridge is what exists right now. See Medicare GLP-1 coverage for the eligibility detail.
NovoCare Pharmacy is the manufacturer selling to you directly
NovoCare Pharmacy is Novo Nordisk's own cash-pay channel, and as of August 2026 it prices the Wegovy pen at $349 a month across the standard doses of 0.25 mg through 2.4 mg, with Wegovy HD 7.2 mg at $399. Patients new to the programme pay $199 a month for their first two fills of the 0.25 mg and 0.5 mg starting doses, an offer running through 31 December 2026. Shipping is free.
Ozempic runs on the same structure: $349 a month for 0.25 mg, 0.5 mg or 1 mg, $499 for the 2 mg pen, with the same $199 introductory fills.
TrumpRx.gov points at the same pricing but does not sell anything itself. It issues a coupon, complete with BIN, PCN and member ID, that you present at a retail pharmacy that dispenses Wegovy. Same $199-then-$349 structure, self-pay only, and it cannot be combined with any insurance claim. It is a distribution front door, not a separate deal. Full breakdown on our semaglutide price page.
Oral semaglutide is real now, and it is the cheapest branded option
The FDA approved the Wegovy pill, once-daily oral semaglutide 25 mg, on 22 December 2025, making it the first oral GLP-1 approved for weight management. It launched on 5 January 2026 and is now stocked at more than 70,000 US pharmacies including CVS and Costco, plus NovoCare Pharmacy, GoodRx and telehealth partners.
Cash pricing runs $149 a month for the 1.5 mg starter dose, $199 for 4 mg, and $299 for 9 mg and 25 mg. Insured patients with the savings offer can pay as little as $25. In the OASIS 4 trial, oral semaglutide 25 mg produced 16.6% mean weight loss when treatment was adhered to.
Separately, Novo renamed Rybelsus. The FDA approved the name-change application on 30 January 2026, and the Ozempic pill, the type 2 diabetes tablet in 1.5 mg, 4 mg and 9 mg, reached pharmacies on 4 May 2026. Same molecule, different indication and different strengths. Our semaglutide tablets page covers what oral semaglutide can and cannot do, including the fact that none of it is available over the counter. Worth noting if you are weighing the two molecules: there is still no oral tirzepatide in any form, approved or compounded, so the injection routes on where to buy tirzepatide are the whole menu there.
Telehealth subscriptions sell the same brand drug, cheaper, for a commitment
On 31 March 2026 Novo Nordisk launched a multi-month subscription for self-pay patients through Ro, WeightWatchers and LifeMD, with Hims & Hers and Sesame joining later. The Wegovy pen runs $329 a month on a 3-month term, $299 on 6 months, and $249 on 12 months. The pill runs $289, $269 and $249 on the same terms.
This is FDA-approved Wegovy, not a compounded substitute. What you are buying with the discount is a commitment: prepaying a term is what gets the price down, and semaglutide is a drug a meaningful share of people stop within the first few months over side effects or cost. Compare platforms on our semaglutide online page, and see cheapest semaglutide for the current lowest verified price across all channels.
Compounded semaglutide: a much narrower lane than it was
The mass-compounding era is over. FDA removed semaglutide from the shortage list in February 2025, and enforcement discretion ended 22 April 2025 for 503A pharmacies and 22 May 2025 for 503B outsourcing facilities. The Outsourcing Facilities Association challenged those determinations in federal court and lost.
On 30 April 2026 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, "finding no clinical need for outsourcing facilities to compound these drugs from bulk substances." Comments closed 29 June 2026 and no final determination has been published as of August 2026.
What remains is the 503A patient-specific lane. A licensed pharmacy can compound for one named patient when the prescriber documents a genuine clinical reason the approved product will not work, such as an allergy to an inactive ingredient or a concentration that is not commercially available. Cost savings and patient preference are explicitly not sufficient justification. Hims & Hers stopped advertising compounded GLP-1s and now offers them only on a limited basis where brand cannot meet a clinical need.
FDA's own concerns page, current as of 15 June 2026, is worth reading before you choose this lane. It records 990 adverse event reports for compounded semaglutide as of 31 May 2026, dosing errors serious enough to require hospitalisation, and fraudulent products whose labels name compounding pharmacies that do not exist. FDA also states it is "not aware of any lawful basis" for compounding with salt forms such as semaglutide sodium or semaglutide acetate.
Research-peptide vendors: unapproved for human use, and named as such
Grey-market vendors sell semaglutide powder labelled "for research purposes only" or "not for human consumption" at prices no regulated channel can match. FDA has issued warning letters to companies doing exactly this, noting the products are "sold directly to consumers for human use with dosing instructions," and urges consumers not to buy them because they are of unknown quality and may be harmful.
This is not a recommendation lane. There is no prescriber, no pharmacy licence, no chain of custody, and no adverse-event reporting obligation. FDA has established import alert 66-80 to stop GLP-1 active ingredients with quality concerns at the border, and separately seized counterfeit Ozempic pens, lot PAR1229, that reached the US supply chain outside Novo's authorised distribution.
If you are going to do this anyway, the harm-reduction floor is a batch-specific certificate of analysis with HPLC purity and mass spec identity, matched to the lot number on the vial in your hand, from a third-party lab you can contact independently. A sitewide PDF that is not tied to your batch tells you nothing. That is a floor, not a safety guarantee, and it does not make the product approved.
Picking your lane in four questions
- Does your plan cover it for weight management? Start the prior authorisation. Nothing beats $0 to $25.
- On Medicare and meeting the BMI criteria? The GLP-1 Bridge is $50 a month through 2027.
- Cash, and open to a tablet? The Wegovy pill at $149 to $299 is the lowest branded price available.
- Cash, and set on the injection? NovoCare at $349, or a 12-month telehealth term at $249 if you are confident you will stay on it.
Frequently Asked Questions
Can I buy semaglutide without a prescription?
Not legally, and not from any channel with a pharmacy licence. Every legitimate route on this page requires a prescription, including NovoCare Pharmacy, TrumpRx coupons and every telehealth subscription. Sites selling semaglutide with no prescriber attached are selling unapproved product, which is the grey market described above.
What is the cheapest way to buy semaglutide right now?
With commercial coverage, the savings card at $0 to $25 a month. Without insurance, the Wegovy pill at $149 a month for the 1.5 mg starter dose. For the injection specifically, a 12-month telehealth subscription at $249 a month beats NovoCare's $349.
Is there a generic semaglutide I can buy in the US?
No. Novo Nordisk's core US compound patent runs to December 2031. Apotex received the first FDA tentative approval for a generic semaglutide injection in April 2026, which confirms the product meets FDA standards but does not permit sale while patents stand. Canada approved its first two generics in April and May 2026 and Indian manufacturers launched after the March 2026 expiry there, but neither is a lawful import route for US patients. See semaglutide generic.
Can I still buy compounded semaglutide online?
Only through a 503A pharmacy filling a patient-specific prescription where your prescriber has documented a clinical reason the approved drug will not work. Broad "compounded semaglutide for $99" marketing no longer has a legal basis, since the shortage exemption ended in 2025 and FDA has proposed closing the 503B bulks pathway as well.
Does Medicare cover semaglutide in 2026?
Yes, for eligible beneficiaries, through the GLP-1 Bridge that started 1 July 2026 and runs through 31 December 2027, at a $50 monthly copay with prior authorisation. Around 10% of beneficiaries are expected to qualify on BMI and related conditions.
Are there semaglutide tablets sold over the counter?
No. Oral semaglutide exists in two approved brands, the Wegovy pill for weight management and the Ozempic pill for type 2 diabetes, and both are prescription-only. Anything sold as an OTC "semaglutide tablet" is not semaglutide.
Sources
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — U.S. Food and Drug Administration
- FDA Warns Consumers Not to Use Counterfeit Ozempic Found in U.S. Drug Supply Chain — U.S. Food and Drug Administration
- Get Your GLP-1 Medications Delivered with NovoCare Pharmacy — NovoCare, Novo Nordisk
- Wegovy Savings Offer — NovoCare, Novo Nordisk
- Wegovy Pen — TrumpRx.gov
- Novo Nordisk Launches First and Only Multi-Month Subscription Program for FDA-Approved Wegovy — Novo Nordisk via PR Newswire
- Novo Nordisk's Wegovy Pill Now Broadly Available Across America — Novo Nordisk via PR Newswire
- What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge — KFF
- 2025 Employer Health Benefits Survey — KFF
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B — Federal Register
- FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs — Orrick
- Your Questions Answered: Off-patent Semaglutide in 2026 — IQVIA
- From Rybelsus to the Ozempic Pill: What Pharmacists Need to Know — Pharmacy Times
